The city of Philadelphia, Pennsylvania, currently has 18 active clinical trials seeking participants for Multiple Sclerosis research studies.
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Recruiting
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
01/26/2024
Locations: Penn Comprehensive MS Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Obesity and Pediatric Multiple Sclerosis
Recruiting
Obesity is one possible contributor to severity of multiple sclerosis and progression of the disease. We already know that obesity is a risk determinant for acquiring MS, yet the impact of obesity on pediatric MS disease expression and course is unknown. This study will evaluate the relationship between obesity, obesity-derived inflammatory mediators, and imaging metrics of MS severity in children. Understanding how childhood obesity contributes to MS severity/progression may yield fundamental i... Read More
Gender:
All
Ages:
Between 10 years and 20 years
Trial Updated:
11/27/2023
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Multiple Sclerosis
Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)
Recruiting
Microparticles (MPs) as a mode of therapeutic delivery can selectively deliver immunomodulatory treatment to the phagocytic cells, particularly dendritic cells (DCs), inducing their tolerogenic phenotype and function and T regulatory (Treg) cell expansion. The study will characterize the in vitro response of cGAMP immunomodulator incapsulated microparticles on the capacity of DCs and Tregs to regulate the inflammatory response.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
01/20/2023
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Relapse Remitting Multiple Sclerosis
Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis
Recruiting
The purpose of this research is to find out how the T regulatory (Treg) cells control autoimmune response in multiple sclerosis. The investigators will identify Treg molecular markers and changes in function in patients with relapse remitting multiple sclerosis (RRMS). The investigators plan to study T regulatory immune cells in the blood of RRMS patients and control subjects to examine how Treg immune cells' deficient function may be involved in the development of mulitple sclerosis.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/13/2022
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Relapse Remitting Multiple Sclerosis
IL-11 in the Development of Multiple Sclerosis
Recruiting
Since the last submission, the investigator have further characterized the potential of IL--11 to induce encephalitogenic CD4+IL--17A+, IL--21+ and GM--CSF+ cells, which upon passive transfer induced severe RREAE with IL--17A+CCR6+ CD4+ cell, neutrophil, CD8+ and B--cell accumulation within the CNS (manuscript submitted for publication). These findings confirmed our hypothesis and further characterization of the IL--11--induced encephalitogenic CD4+ cells will be performed as planned in the gran... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/03/2022
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Multiple Sclerosis
ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program
Recruiting
The investigators have previously shown that youth with MS are very inactive, and that vigorous physical activity is associated with higher levels of well-being and lower MS disease activity in youth. Yet, no effective physical activity interventions have been developed for youth with MS to date. The investigators have taken input from youth with MS to create a Smartphone-based app (the ATOMIC - Active Teens with Multiple Sclerosis - App) that provides tailored physical activity information and... Read More
Gender:
All
Ages:
Between 11 years and 21 years
Trial Updated:
03/15/2022
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Pediatric Multiple Sclerosis